![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Neuropharm | LSE:NPH | London | Ordinary Share | GB00B1NPJJ01 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMNPH RNS Number : 1069L Neuropharm Group PLC 30 April 2010 +------------------------------------+------------------------------+ | For immediate release | 30 April 2010 | +------------------------------------+------------------------------+ Neuropharm Group plc ("Neuropharm" or the "Company") Issue of Equity Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, announces the issue of 1,200,000 new ordinary shares of 10p each in the Company ("Ordinary Shares") following the exercise of options granted to Professor Eric Hollander and Professor Mark Smith in March 2006. As a result, the Company's issued share capital now consists of 32,736,697 ordinary shares of 10p each, with one voting right per share. The Company holds no ordinary shares in Treasury, therefore, the total number of voting rights in the Company is 32,736,697. For further information please contact: +----------------------------------------+----------------+ | Neuropharm | + 44 (0) 1372 | | | 371 171 | +----------------------------------------+----------------+ | Robert Mansfield, Chief Executive | | | Officer | | | Graham Yeatman, Chief Financial | | | Officer | | +----------------------------------------+----------------+ | | | +----------------------------------------+----------------+ | Piper Jaffray Ltd. | + 44 (0) 20 | | | 3142 8700 | +----------------------------------------+----------------+ | Neil Mackison, Rupert Winckler | | +----------------------------------------+----------------+ | | | +----------------------------------------+----------------+ | Buchanan Communications | + 44 (0) 20 | | | 7466 5000 | +----------------------------------------+----------------+ | Mark Court, Catherine Breen | | +----------------------------------------+----------------+ Notes to Editors: About Neuropharm Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information. This information is provided by RNS The company news service from the London Stock Exchange END IOEZBLBXBZFXBBZ
1 Year Neuropharm Chart |
1 Month Neuropharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions